Retinal cell replacement therapy method for treating retinal diseases

By collecting cells from patients or healthy donors, obtaining high-purity retinal cells using inducible pluripotent stem cells and sorting techniques, combined with minimally invasive surgery and immunosuppressive therapy, the problem of cell source and survival in retinal cell replacement therapy is solved. Significantly improves the therapeutic effect.

CN118987045APending Publication Date: 2024-11-22SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410948778.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing retinal cell replacement therapy has many challenges in cell source, transplant efficiency and survival, making it difficult to effectively obtain high-purity, high-quality retinal cells and ensure their survival and functional recovery after transplantation.

Method used

By collecting cells from the patient's own or healthy donor, using inducible pluripotent stem cells for retinal differentiation, combining flow cytometry or magnetic bead sorting technology to obtain high-purity retinal cells, and pre-culture in specific culture media, using microscope Invasive surgical techniques are used for transplantation, immunosuppressive treatment and retinal protection measures are carried out.

Benefits of technology

It significantly improves the survival rate and functional recovery effect of transplanted cells, provides a variety of cell source choices, ensures the availability of cells and the effectiveness of treatment, and provides a new way for the treatment of retinal diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987045A_ABST
    Figure CN118987045A_ABST
Patent Text Reader

Abstract

The invention discloses a retinal cell replacement therapy method for treating retinal diseases, which comprises the following steps: acquiring cells from skin cells of a patient or corneal limbus tissues of a healthy donor, generating induced pluripotent stem cells by a reprogramming technology, or obtaining retinal photoreceptor cells by in vitro amplification and differentiation; carrying out cell differentiation in a culture medium containing a retinal differentiation factor; carrying out cell purification by adopting a flow cytometry or a magnetic bead sorting technology; pre-culturing in a specific culture medium containing growth factors, anti-apoptosis factors and extracellular matrix proteins; according to the method, retina cell transplantation is performed by using a minimally invasive surgery technology, and immunosuppression treatment and retina protection are performed, so that various cell source selections are provided, the availability of the cells and the effectiveness of treatment are ensured, and the survival rate and the function recovery effect of the cells are remarkably improved through a series of optimization steps; and a new way is provided for treatment of retinal diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of retinal cell replacement, and more particularly to a retinal cell replacement therapy method for treating retinal diseases. Background Art

[0002] Retinal diseases, such as macular degeneration, retinitis pigmentosa, and diabetic retinopathy, are among the leading causes of blindness. These diseases typically involve the degeneration or death of retinal cells, leading to a gradual loss of vision. Existing treatments mainly include medication, laser surgery, and photodynamic therapy, but these methods can usually only delay disease progression and are unlikely to restore lost vision.

[0003] In recent years, cell replacement therapy has attracted much attention as a potential treatment method. By transplanting healthy retinal cells into damaged areas, diseased or dead retinal cells can be replaced, thereby restoring vision. However, current cell replacement therapies still face many challenges in terms of cell sources, transplantation efficiency, and survival rates. How to effectively obtain high-purity, high-quality retinal cells and ensure their survival and functional recovery after transplantation is an urgent problem to be solved.

[0004] Therefore, in view of the above technical problems, it is necessary to provide a retinal cell replacement therapy method for treating retinal diseases. Summary of the invention

[0005] The object of the present invention is to provide a retinal cell replacement therapy method for treating retinal diseases to solve the above-mentioned problems.

[0006] In order to achieve the above purpose, the technical solution provided by an embodiment of the present invention is as follows:

[0007] A retinal cell replacement therapy method for treating retinal diseases, comprising:

[0008] S1: Collect cells from the patient or healthy donor, preferably using induced pluripotent stem cells;

[0009] S2: The collected cells are cultured in a culture medium containing retinal differentiation factors to induce them to differentiate into retinal cells, which include photoreceptor cells and retinal pigment epithelial cells;

[0010] S3: Isolate high-purity target retinal cells by flow cytometry or magnetic bead sorting technology;

[0011] S4: Purified retinal cells are pre-cultured in a specific culture medium containing growth factors, anti-apoptotic factors, and extracellular matrix proteins;

[0012] S5: Using minimally invasive surgical techniques, the processed retinal cells are transplanted into the patient's retinal diseased area;

[0013] S6: After transplantation, patients should receive immunosuppressive therapy and retinal protection measures to promote the survival and functional recovery of transplanted cells.

[0014] As a further improvement of the present invention, the cell source in step S1 is the patient's own skin cells, and induced pluripotent stem cells are generated through reprogramming technology.

[0015] As a further improvement of the present invention, the cells in step S1 also include corneal limbal tissue from a healthy donor, and retinal photoreceptor cells are obtained through in vitro expansion and differentiation.

[0016] As a further improvement of the present invention, the retinal differentiation factor in step S2 includes any one of retinoic acid, fibroblast growth factor (FGF) and insulin-like growth factor (IGF).

[0017] As a further improvement of the present invention, flow cytometry or magnetic bead sorting technology is used in step S3 to separate retinal pigment epithelial cells and photoreceptor cells. The specific operation steps are as follows:

[0018] S31: cultured retinal cells were suspended in flow cytometry buffer;

[0019] S32: Isolation of retinal pigment epithelial cells and photoreceptor cells by flow cytometry based on cell surface markers;

[0020] S33: Alternatively, magnetic bead sorting technology can be used to mix magnetic beads labeled with specific antibodies with retinal cells, and the target retinal cells can be separated through a magnetic field.

[0021] As a further improvement of the present invention, the specific culture medium in step S4 contains growth factors, including any one of brain-derived neurotrophic factor (BDNF), anti-apoptotic factors such as Bcl-2, and extracellular matrix proteins.

[0022] As a further improvement of the present invention, the retinal cell transplantation in step S5 is performed using minimally invasive surgical techniques, including any one of intravitreal injection and subretinal injection.

[0023] As a further improvement of the present invention, in step S6, after the transplantation, the patient is given immunosuppressive treatment with cyclosporine A or tacrolimus, supplemented with antioxidants and retinal protective agents.

[0024] As a further improvement of the present invention, the step S5 uses biomaterials to construct a three-dimensional cell scaffold to provide a better cell microenvironment, and the biomaterials include any one of collagen, gelatin and polyethylene glycol.

[0025] As a further improvement of the present invention, the step S6 is combined with local or systemic drug therapy or gene therapy to enhance the survival rate and functional recovery effect of the transplanted cells, and the drug includes any one of anti-inflammatory drugs, antioxidants and neurotrophic factors.

[0026] Compared with the prior art, the advantages of the present invention are:

[0027] This program significantly improves the survival rate and functional recovery effect of transplanted cells by improving cell preparation and transplantation technology. Specifically, the method includes obtaining cells from the patient's own skin cells or the corneal limbal tissue of a healthy donor, generating induced pluripotent stem cells (iPS cells) through reprogramming technology, or obtaining retinal photoreceptor cells through in vitro expansion and differentiation; cell differentiation in a culture medium containing retinal differentiation factors; cell purification using flow cytometry or magnetic bead sorting technology; pre-culture in a specific culture medium containing growth factors, anti-apoptotic factors and extracellular matrix proteins; retinal cell transplantation using minimally invasive surgical techniques, and immunosuppressive therapy and retinal protection. It not only provides a variety of cell source options to ensure the availability of cells and the effectiveness of treatment, but also significantly improves the survival rate and functional recovery effect of cells through a series of optimization steps, providing a new approach for the treatment of retinal diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 This is a schematic diagram of a retinal cell replacement therapy method for treating retinal diseases according to the present invention. DETAILED DESCRIPTION

[0029] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention; it is obvious that the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments, and all other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making creative work are within the scope of protection of the present invention.

[0030] Example:

[0031] See also Figure 1 , a retinal cell replacement therapy method for treating retinal diseases, comprising:

[0032] S1: Collect cells from the patient or healthy donor, preferably using induced pluripotent stem cells;

[0033] S2: The collected cells are cultured in a culture medium containing retinal differentiation factors to induce them to differentiate into retinal cells, which include photoreceptor cells and retinal pigment epithelial cells;

[0034] S3: Isolate high-purity target retinal cells by flow cytometry or magnetic bead sorting technology;

[0035] S4: Purified retinal cells are pre-cultured in a specific culture medium containing growth factors, anti-apoptotic factors, and extracellular matrix proteins;

[0036] S5: Using minimally invasive surgical techniques, the processed retinal cells are transplanted into the patient's retinal diseased area;

[0037] S6: After transplantation, patients should receive immunosuppressive therapy and retinal protection measures to promote the survival and functional recovery of transplanted cells.

[0038] Among them, by improving cell preparation and transplantation technology, the survival rate and functional recovery effect of transplanted cells have been significantly improved. Specifically, the method includes obtaining cells from the patient's own skin cells or the corneal limbal tissue of a healthy donor, generating induced pluripotent stem cells (iPS cells) through reprogramming technology, or obtaining retinal photoreceptor cells through in vitro expansion and differentiation; cell differentiation in a culture medium containing retinal differentiation factors; cell purification using flow cytometry or magnetic bead sorting technology; pre-culture in a specific culture medium containing growth factors, anti-apoptotic factors and extracellular matrix proteins; retinal cell transplantation using minimally invasive surgical techniques, and immunosuppressive therapy and retinal protection, which not only provides a variety of cell source options, ensures the availability of cells and the effectiveness of treatment, but also significantly improves the survival rate and functional recovery effect of cells through a series of optimization steps, providing a new approach for the treatment of retinal diseases.

[0039] The cells in step S1 are derived from the patient's own skin cells, which are used to generate induced pluripotent stem cells through reprogramming technology. The cells in step S1 also include limbal tissue from healthy donors, which are used to obtain retinal photoreceptor cells through in vitro expansion and differentiation.

[0040] Among them, in the S1 step, there are two options for the source of cells: one is to extract from the patient's own skin cells, and transform these cells into induced pluripotent stem cells (iPS cells) through reprogramming technology. These iPS cells have multidirectional differentiation capabilities and can differentiate into target retinal cells under specific conditions; the other is to extract cells from the corneal limbus tissue of healthy donors and directly obtain retinal photoreceptor cells through in vitro expansion and differentiation technology. Both of the above methods can produce cells for the treatment of retinal diseases, providing a variety of cell source options for cell replacement therapy, ensuring the availability of cells and the effectiveness of treatment.

[0041] The retinal differentiation factor in step S2 includes any one of retinoic acid, fibroblast growth factor (FGF) and insulin-like growth factor (IGF).

[0042] Among them, in step S2, the cell differentiation process needs to be carried out in a culture medium containing retinal differentiation factors, which can promote the differentiation of cells into specific directions of retinal cells. Retinal differentiation factors include any one of retinoic acid, fibroblast growth factor (FGF) and insulin-like growth factor (IGF). Retinoic acid is a vitamin A derivative that can induce stem cells to differentiate into nerve cells; fibroblast growth factor (FGF) is an important signaling molecule that can promote cell proliferation and differentiation; insulin-like growth factor (IGF) enhances the differentiation potential of cells by promoting cell growth and survival. The presence of the above differentiation factors in the culture medium ensures that the cells can effectively differentiate into photoreceptor cells and retinal pigment epithelial cells, providing functional cells required for the treatment of retinal diseases.

[0043] In step S3, flow cytometry or magnetic bead sorting technology is used to separate retinal pigment epithelial cells and photoreceptor cells. The specific steps are as follows:

[0044] S31: cultured retinal cells were suspended in flow cytometry buffer;

[0045] S32: Isolation of retinal pigment epithelial cells and photoreceptor cells by flow cytometry based on cell surface markers;

[0046] S33: Alternatively, magnetic bead sorting technology can be used to mix magnetic beads labeled with specific antibodies with retinal cells, and the target retinal cells can be separated through a magnetic field.

[0047] First, the retinal cells differentiated in the culture medium are suspended in a flow cytometer buffer for subsequent sorting operations. The buffer can maintain the stability and activity of the cells. Next, the cells are sorted by flow cytometry based on cell surface markers. Flow cytometry uses lasers and fluorescent markers to identify and distinguish different types of cells, and then separates retinal pigment epithelial cells and photoreceptor cells. This process relies on specific markers on the cell surface, which enables efficient acquisition of high-purity target cells.

[0048] Alternatively, magnetic beads labeled with specific antibodies can be mixed with retinal cells using magnetic bead sorting technology. Specific antibodies will bind to markers on the surface of target cells, and through the action of the magnetic field, target retinal cells (retinal pigment epithelial cells and photoreceptor cells) will be separated from the mixed cell population. Magnetic bead sorting technology can also effectively separate high-purity target cells.

[0049] Through the above specific operation steps, high-purity retinal pigment epithelial cells and photoreceptor cells can be effectively obtained, providing high-quality cell materials for subsequent pre-culture and transplantation steps.

[0050] The specific culture medium in step S4 contains growth factors including brain-derived neurotrophic factor (BDNF), anti-apoptotic factors such as Bcl-2, and any one of extracellular matrix proteins.

[0051] Among them, brain-derived neurotrophic factor (BDNF) is a neurotrophic factor that can promote the growth, survival and differentiation of nerve cells, and the anti-apoptotic factor Bcl-2 is an important cell protection protein that can inhibit cell apoptosis, prolong cell survival time, and ensure that transplanted cells can survive and function better in the body. Extracellular matrix proteins include any one of laminin, gelatin and polyethylene glycol, which constitute the external support structure of cells, can provide the microenvironment required for cell attachment and growth, and promote cell adhesion, migration and differentiation.

[0052] By pre-culturing in a specific culture medium containing these components, the activity and survival rate of retinal cells can be significantly improved, providing higher quality cell material for subsequent cell transplantation and ensuring that the transplanted cells can better integrate and exert a therapeutic effect in the patient's body.

[0053] In step S5, retinal cell transplantation is performed using minimally invasive surgical techniques, including either intravitreal injection or subretinal injection. In step S5, biomaterials are used to construct a three-dimensional cell scaffold to provide a better cell microenvironment. The biomaterials include either collagen, gelatin, and polyethylene glycol.

[0054] Among them, intravitreal injection injects retinal cells into the vitreous cavity of the eyeball, which can deliver cells to the diseased area without damaging the retina. Subretinal injection injects retinal cells directly into the subretinal cavity, which is closer to the natural growth environment of retinal cells and helps the integration and function of cells.

[0055] Before the above minimally invasive surgery, biomaterials are used to construct a three-dimensional cell scaffold to provide a better cell microenvironment. The three-dimensional cell scaffold simulates the natural growth environment of cells in the body and can support cell attachment, growth and differentiation.

[0056] Collagen is the main component of the extracellular matrix, has good biocompatibility and degradability, and can provide structural support and signal transmission for cells; gelatin is derived from collagen, has similar biocompatibility and degradability, and can be easily processed into various forms to meet different cell culture needs; polyethylene glycol (PEG) has good biocompatibility and controllable mechanical properties, and is often used to construct adjustable cell scaffolds.

[0057] In step S6, after transplantation, the patient is given immunosuppressive treatment with cyclosporine A or tacrolimus, supplemented with antioxidants and retinal protectants. In step S6, local or systemic drug therapy or gene therapy is combined to enhance the survival rate and functional recovery of transplanted cells. The drugs include any one of anti-inflammatory drugs, antioxidants and neurotrophic factors.

[0058] Among them, immunosuppressants such as cyclosporine A or tacrolimus are used to prevent the patient's immune system from rejecting the transplanted retinal cells. Cyclosporine A and tacrolimus are commonly used immunosuppressive drugs that can effectively inhibit the activation and proliferation of T cells, thereby reducing the risk of transplanted cells being attacked and rejected.

[0059] After transplantation, antioxidants and retinal protectants are used to reduce oxidative stress and protect retinal cells. Antioxidants can neutralize free radicals and reduce cell damage; retinal protectants can enhance the tolerance and function of retinal cells.

[0060] Combined with local or systemic drug therapy or gene therapy, the survival rate and functional recovery of transplanted cells can be enhanced. Specific drugs include:

[0061] Anti-inflammatory drugs: used to reduce inflammatory responses and protect transplanted cells from inflammation-mediated damage;

[0062] Antioxidants: Protect cells from oxidative damage and promote cell survival and function by reducing oxidative stress;

[0063] Neurotrophic factors: brain-derived neurotrophic factor (BDNF), etc., can promote the growth and functional recovery of nerve cells and support the survival and integration of retinal cells.

[0064] Through the above-mentioned comprehensive treatment measures, the success rate of retinal cell transplantation can be significantly improved, and the survival and functional recovery of transplanted cells in the patient's body can be promoted, thereby achieving the purpose of treating retinal diseases. The synergistic effect of these measures ensures that the transplanted cells can better adapt to and exert their therapeutic functions in the complex in vivo environment.

[0065] It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and scope of the equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.

[0066] In addition, it should be understood that although the present specification is described according to embodiments, not every embodiment contains only one independent technical solution. This narrative method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation methods that those skilled in the art can understand.

Claims

1. A retinal cell replacement therapy method for treating retinal diseases, characterized in that: include: S1: Collect cells from the patient or healthy donor, preferably using induced pluripotent stem cells; S2: The collected cells are cultured in a culture medium containing retinal differentiation factors to induce them to differentiate into retinal cells, which include photoreceptor cells and retinal pigment epithelial cells; S3: Isolate high-purity target retinal cells by flow cytometry or magnetic bead sorting technology; S4: Purified retinal cells are pre-cultured in a specific culture medium containing growth factors, anti-apoptotic factors, and extracellular matrix proteins; S5: Using minimally invasive surgical techniques, the processed retinal cells are transplanted into the patient's retinal diseased area; S6: After transplantation, patients should receive immunosuppressive therapy and retinal protection measures to promote the survival and functional recovery of transplanted cells.

2. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: The cells in step S1 are derived from the patient's own skin cells, which are used to generate induced pluripotent stem cells through reprogramming technology.

3. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: The cells in step S1 also include corneal limbal tissue from a healthy donor, and retinal photoreceptor cells are obtained by in vitro expansion and differentiation.

4. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: The retinal differentiation factor in step S2 includes any one of retinoic acid, fibroblast growth factor (FGF) and insulin-like growth factor (IGF).

5. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: In the step S3, flow cytometry or magnetic bead sorting technology is used to separate retinal pigment epithelial cells and photoreceptor cells. The specific operation steps are as follows: S31: cultured retinal cells were suspended in flow cytometry buffer; S32: Isolation of retinal pigment epithelial cells and photoreceptor cells by flow cytometry based on cell surface markers; S33: Alternatively, magnetic bead sorting technology can be used to mix magnetic beads labeled with specific antibodies with retinal cells, and the target retinal cells can be separated through a magnetic field.

6. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: The specific culture medium in step S4 contains growth factors, including any one of brain-derived neurotrophic factor (BDNF), anti-apoptotic factors such as Bcl-2, and extracellular matrix proteins.

7. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: In step S5, the retinal cell transplantation is performed using minimally invasive surgical techniques, including either intravitreal injection or subretinal injection.

8. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: In the S6 step, after transplantation, the patient is given immunosuppressive treatment with cyclosporine A or tacrolimus, supplemented with antioxidants and retinal protective agents.

9. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: Before the S5 step, a three-dimensional cell scaffold is constructed using biological materials to provide a better cell microenvironment, and the biological material includes any one of collagen, gelatin and polyethylene glycol.

10. A retinal cell replacement therapy method for treating retinal diseases according to claim 1, characterized in that: The step S6 is combined with local or systemic drug therapy or gene therapy to enhance the survival rate and functional recovery effect of transplanted cells, and the drug includes any one of anti-inflammatory drugs, antioxidants and neurotrophic factors.